jrnl1289

Publication Venue For

  • Sustained blood pressure control and coronary heart disease, stroke, heart failure, and mortality: An observational analysis of ALLHAT.  21:451-459. 2019
  • Race and sex differences in asleep blood pressure: The Coronary Artery Risk Development in Young Adults (CARDIA) study.  21:184-192. 2019
  • Angiotensin II receptor blocker attenuates stress pressor response in young adult African Americans.  21:1191-1199. 2019
  • Drugs don’t work in patients who don’t take them.  20:1504-1506. 2018
  • Primary prevention of chronic kidney disease through population-based strategies for blood pressure control: The ARIC study.  20:1018-1026. 2018
  • Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease.  20:694-702. 2018
  • The association of nocturnal hypertension and nondipping blood pressure with treatment-resistant hypertension: The Jackson Heart Study.  20:438-446. 2018
  • Measure Accurately, Act Rapidly, and Partner With Patients (MAP) improves hypertension control in medically underserved patients: Care Coordination Institute and American Medical Association Hypertension Control Project Pilot Study results.  20:79-87. 2018
  • Chronic kidney disease and incident apparent treatment-resistant hypertension among blacks: Data from the Jackson Heart Study.  19:1117-1124. 2017
  • The association between insulin resistance and atrial fibrillation: A cross-sectional analysis from SPRINT (Systolic Blood Pressure Intervention Trial).  19:1152-1161. 2017
  • Metabolic syndrome and masked hypertension among African Americans: The Jackson Heart Study.  19:592-600. 2017
  • Evaluation of Criteria to Detect Masked Hypertension.  18:1086-1094. 2016
  • Dietary Total Isoflavone Intake Is Associated With Lower Systolic Blood Pressure: The Coronary Artery Risk Development in Young Adults (CARDIA) Study.  18:778-783. 2016
  • White-Coat Effect Among Older Adults: Data From the Jackson Heart Study.  18:139-145. 2016
  • Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: Results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial.  16:323-330. 2014
  • Resting energy expenditure and systolic blood pressure relationships in women across 4.5 years.  16:172-176. 2014
  • Trends in hypertension prevalence, awareness, treatment, and control among us adults 80 years and older, 1988-2010.  16:270-276. 2014
  • Author Response to Lipid-Lowering in African Americans in ALLHAT-Optimism Bias?.  15:941-941. 2013
  • Risk of Hospitalized Gastrointestinal Bleeding in Persons Randomized to Diuretic, ACE-Inhibitor, or Calcium-Channel Blocker in ALLHAT.  15:825-832. 2013
  • The Human Side of Failed Hypertension Treatment.  15:762-764. 2013
  • Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT).  15:542-554. 2013
  • Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: A TRINITY subanalysis.  15:584-592. 2013
  • Changes in Vascular Hemodynamics in Older Women Following 16 Weeks of Combined Aerobic and Resistance Training.  15:241-246. 2013
  • Reply to Visit-to-Visit Blood Pressure Variation: Time to Reanalyze All The Data From the TROPHY Study.  15:301. 2013
  • Association Between Antihypertensive Medication Adherence and Visit-to-Visit Variability of Blood Pressure.  15:112-117. 2013
  • Randomized Study of Antihypertensive Efficacy and Safety of Combination Aliskiren/Valsartan vs Valsartan Monotherapy in Hypertensive Participants With Type 2 Diabetes Mellitus.  15:92-100. 2013
  • Blood Pressure Measurement Device, Number and Timing of Visits, and Intra-Individual Visit-to-Visit Variability of Blood Pressure.  14:744-750. 2012
  • The Role of Uric Acid in the Pathogenesis of Hypertension in the Young.  14:346-352. 2012
  • Hypertension Control Among Newly Treated Patients Before and After Publication of the Main ALLHAT Results and JNC 7 Guidelines.  14:277-283. 2012
  • Long-Term Efficacy and Safety of Triple-Combination Therapy With Olmesartan Medoxomil and Amlodipine Besylate and Hydrochlorothiazide for Hypertension.  14:149-157. 2012
  • Antiplatelet therapy for transient ischemic attack.  14:103-111. 2012
  • Mortality and morbidity during and after the antihypertensive and lipid-lowering treatment to prevent heart attack trial.  14:20-31. 2012
  • Prevalence and Correlates of Low Medication Adherence in Apparent Treatment-Resistant Hypertension.  14:694-700. 2012
  • Refractory hypertension: Definition, prevalence, and patient characteristics.  14:7-12. 2012
  • Within-Visit Variability of Blood Pressure and All-Cause and Cardiovascular Mortality Among US Adults.  14:165-171. 2012
  • 24-Hour Efficacy and Safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: The TRINITY Ambulatory Blood Pressure Substudy.  13:873-880. 2011
  • Low medication adherence and the incidence of stroke symptoms among individuals with hypertension: The REGARDS study.  13:479-486. 2011
  • Efficacy of an olmesartan medoxomil-based treatment algorithm in patients stratified by age, race, or sex.  12:3-13. 2010
  • Taking less than prescribed: Medication nonadherence and provider-patient relationships in lower-income, rural minority adults with hypertension.  12:706-713. 2010
  • Prevention of Microalbuminuria in Patients With Type 2 Diabetes: What Do We Know?.  12:422-430. 2010
  • ASH Position Paper: Dietary approaches to lower blood pressure..  11:358-368. 2009
  • Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension.  11:475-482. 2009
  • ASH position paper: Treatment of hypertension in patients with diabetes - An update.  10:707-713. 2008
  • Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients.  10:911-921. 2008
  • Mechanisms and treatment of resistant hypertension.  10:239-244. 2008
  • The ALLHAT study revisited: do newer data from this trial and others indicate changes in treatment guidelines?.  9:372-380. 2007
  • Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension..  9:187-195. 2007
  • Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension..  9:19-24. 2007
  • Renin inhibitors in the management of hypertension..  9:706-707. 2007
  • American Society of Hypertension, Inc
Leadership Message.  8:904-905. 2006
  • Efficacy and Safety of Irbesartan/HCTZ Combination Therapy As Initial Treatment for Rapid Control of Severe Hypertension.  8:850-859. 2006
  • Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)..  8. 2006
  • Primary Aldosteronism: Diagnosis and Treatment.  8:887-893. 2006
  • Resistant or difficult-to-treat hypertension..  8:181-186. 2006
  • Conflicting and confusing data from the hypertension treatment trials: whom and what should you believe?.  7:403-408. 2005
  • Ethnicity and blood pressure..  7:357-364. 2005
  • Gender and blood pressure..  7:300-309. 2005
  • New-onset diabetes in treated hypertensive patients--is it clinically significant? Roundtable discussion..  7:90-95. 2005
  • The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study..  7:152-158. 2005
  • Interview with Suzanne Oparil, MD. Interview by Marvin Moser, MD..  6:509-512. 2004
  • Roundtable discussion: blood pressure goal attainment: meeting the challenge of the JNC 7's blood pressure goals and the role of renin-angiotensin-aldosterone system blockade..  6:699-705. 2004
  • Use of aldosterone antagonists in resistant hypertension..  6:458-460. 2004
  • Erratum: Comparative efficacy of olmesartan, losartan, valsartan and irbesartan in the control of essential hypertension (Journal of Clinical Hypertension (2001) vol. 3(5) (283-291, 318)).  3:395. 2001
  • Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.  3. 2001
  • Primary aldosteronism: A practical approach to diagnosis and treatment.  3:189-195. 2001
  • Treating hypertension in the elderly - Whom to treat, when, and with what?.  3:103-109. 2001
  • The use of transcutaneous clonidine hydrochloride in the patient with diabetes mellitus and mild hypertension..  1:315-321. 1985